229 assets in Metastatic Prostate Carcinoma

Therapeutic assets addressing Metastatic Prostate Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludrocortisone Metastatic Prostate Carcinoma	Merck Sharp & Dohme LLC	P3	B (56)
Lutetium (<Sup>177</Sup>Lu) Zadavotide Guraxetan Metastatic Prostate Carcinoma	Jonsson Comprehensive Cancer Center	P3	B (56)
Rucaparib Metastatic Prostate Carcinoma	pharmaand GmbH	P3	B (56)
Xaluritamig Metastatic Prostate Carcinoma	Amgen	P3	B (56)
Dentalfluoro Metastatic Prostate Carcinoma	National Cancer Institute (NCI)	P2	CCC (55)
Testosterone Cipionate Metastatic Prostate Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (55)
Atorvastatin Metastatic Prostate Carcinoma	Tampere University Hospital	P3	CCC (54)
Denosumab Metastatic Prostate Carcinoma	Swiss Cancer Institute	P3	CCC (54)
Hydrocortisone Metastatic Prostate Carcinoma	Merck Sharp & Dohme LLC	P3	CCC (54)
Metformin Metastatic Prostate Carcinoma	Sun Yat-sen University	P2	CCC (54)
ac0010ma Metastatic Prostate Carcinoma	Sorrento Therapeutics, Inc.	P2	CCC (53)
Adebrelimab Metastatic Prostate Carcinoma	Fudan University	P2	CCC (53)
Berzosertib Metastatic Prostate Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cetrelimab Metastatic Prostate Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Fezolinetant Metastatic Prostate Carcinoma	Shehzad Basaria, M.D.	P2	CCC (53)
Goserelin Microspheres For Metastatic Prostate Carcinoma	The First Affiliated Hospital of Xiamen University	P2	CCC (53)
Hrs-2189 Metastatic Prostate Carcinoma	Fudan University	P2	CCC (53)
Hrs-5041 Metastatic Prostate Carcinoma	Fudan University	P2	CCC (53)
hs-20093 Metastatic Prostate Carcinoma	Hansoh BioMedical R&D Company	P2	CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Metastatic Prostate Carcinoma	Mark Stein	P2	CCC (53)
Prednisolone Metastatic Prostate Carcinoma	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	CCC (53)
Quemliclustat Metastatic Prostate Carcinoma	Catherine Spina	P2	CCC (53)
Tislelizumab Metastatic Prostate Carcinoma	The First Affiliated Hospital of Xiamen University	P2	CCC (53)
Trametinib Metastatic Prostate Carcinoma	Jonsson Comprehensive Cancer Center	P2	CCC (53)
Trastuzumab Deruxtecan Metastatic Prostate Carcinoma	Washington D.C. Veterans Affairs Medical Center	P2	CCC (53)
Zopocianine Metastatic Prostate Carcinoma	Clinton Bahler	P2	CCC (53)
asp5541 Metastatic Prostate Carcinoma	Astellas Pharma Global Development, Inc.	P2	CCC (52)
Bms-986365 Metastatic Prostate Carcinoma	Celgene	P3	CCC (52)
bnt324 Metastatic Prostate Carcinoma	BioNTech SE	P3	CCC (52)
Capecitabine Metastatic Prostate Carcinoma	AstraZeneca	P2	CCC (52)
Fluorouracilum Metastatic Prostate Carcinoma	Parabilis Medicines, Inc.	P2	CCC (52)
Flutamide Metastatic Prostate Carcinoma	VA Office of Research and Development	P2/3	CCC (52)
Histrelin Metastatic Prostate Carcinoma	VA Office of Research and Development	P2/3	CCC (52)
Lenvatinib Metastatic Prostate Carcinoma	University of Michigan Rogel Cancer Center	P2	CCC (52)
Nilutamide Metastatic Prostate Carcinoma	VA Office of Research and Development	P2/3	CCC (52)
sv-102 Metastatic Prostate Carcinoma	Syncromune, Inc.	P2	CCC (52)
Zanzalintinib Metastatic Prostate Carcinoma	Pedro Barata, MD, MSc	P2	CCC (52)
Dapagliflozin Metastatic Prostate Carcinoma	Yung NA	P2	CCC (51)
Naltrexone Metastatic Prostate Carcinoma	University of Arkansas	P2	CCC (51)
Tarlatamab Metastatic Prostate Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (51)
Testosterone Undecylate Metastatic Prostate Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (51)
Vandazole Metastatic Prostate Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (51)
Avelumab Metastatic Prostate Carcinoma	Exelixis	P2	CCC (50)
[177lu]ludotadipep Metastatic Prostate Carcinoma	FutureChem	P1/2	CCC (49)
for46 Metastatic Prostate Carcinoma	Rahul Aggarwal	P1/2	CCC (49)
HP518 Metastatic Prostate Carcinoma	Hinova Pharmaceuticals Inc.	P1/2	CCC (49)
Pegfilgrastim Metastatic Prostate Carcinoma	Rahul Aggarwal	P1/2	CCC (49)
177lu-psma Metastatic Prostate Carcinoma	Peter MacCallum Cancer Centre, Australia	P2	CCC (48)
Adrenocorticotropic Hormone Metastatic Prostate Carcinoma	Astellas Pharma Global Development, Inc.	P2	CCC (48)
AZD2287 Metastatic Prostate Carcinoma	AstraZeneca	P1/2	CCC (48)

Showing 51 to 100 of 229 assets

PreviousPage 2 of 5Next